Key Takeaways
The force behind KOSPI's first-half rally was large-cap semiconductor stocks. But the very rally they produced is now complicating second-half strategy. Korea's securities industry (Yeouido) warns that putting 100% of a portfolio into semiconductors alone won't work in the second half, and while KOSPI and large-cap chip stocks trade sideways, recommends shifting half of that allocation into KOSDAQ biotech.
What Happened
The gist of the advice relayed by Maeil Business Newspaper's securities column "Yeouido Rando-rando" is simple: investors who profited in the first half by going all-in on semiconductors will find it hard to repeat that same approach in the second half. The premise is that large-cap chip stocks have already priced in much of the market's expectations through their first-half sharp gain (surge), making it increasingly likely that KOSPI and large-cap semiconductor stocks will trade in a range without a clear direction.
The proposed alternative is KOSDAQ biotech. The logic is that capital could rotate into a sector that has been relatively neglected while semiconductors take a breather — and notably, the recommendation isn't to "swap out entirely" but to rebalance by "trimming half the position."
Background and Context
The first half, when going all-in on semiconductors worked, was in fact a special phase — a stretch where a strong rally concentrated in a handful of industry sectors dragged the whole index along, so focusing solely on that sector alone generated excess returns. The problem is that in phases like this, valuations (multiples) tend to rise ahead of the pace of earnings improvement. Once share prices have gotten ahead of earnings, further upside tends to come not from fresh news but merely from reconfirming already-known positive catalysts — which is the basis for the sideways-range outlook.
Impact on the Market and Individual Stocks
- Samsung Electronics (005930) / SK Hynix (000660) — Both held their position as first-half market leaders, but further gains now require new earnings or supply-demand (order flow) triggers that go beyond expectations already priced in.
- Large-cap KOSDAQ biotech names (Samsung Biologics, Celltrion, Yuhan Corporation, etc.) — Having been relatively overlooked compared with semiconductors, they're cited as prime candidates to benefit first from rotating capital.
- Small- and mid-cap semiconductor equipment/materials suppliers — If the large-cap trading range drags on, expectations of a trickle-down effect could weaken, putting near-term supply-demand (order flow) at a disadvantage.
- KOSDAQ index broadly — If the capital rotation into biotech materializes, relative strength versus KOSPI could improve.
Investor Checkpoints
- Next-quarter earnings guidance from large-cap semiconductor names and updates on HBM/foundry utilization rates — watch for whether these could break the sideways-range outlook.
- The strength of capital inflows into the KOSDAQ biotech industry sector (supply-demand (order flow) data) — a leading indicator of whether the advice is translating into actual capital movement.
- KOSPI valuation trends (12-month forward P/E) — check where the semiconductor-heavy index's multiple stands relative to earnings expectations.
- Clinical trial and technology out-licensing schedules for individual biotech stocks (tickers) — a reversal risk if rotating capital chases expectations alone without earnings support.
Outlook
In the optimistic scenario, biotech establishes itself as an alternative market leader backed by both earnings and momentum while semiconductors take a breather — in which case the index could keep climbing through this sector rotation. Conversely, if biotech also rallies purely on rotation expectations without clinical results or out-licensing achievements, it risks taking on the same valuation burden as semiconductors, only faster. The advice to shift only half the allocation is itself evidence that this rotation is a probability-based bet, not a certainty.
Samsung Electronics: Real-Time Data Snapshot
Samsung Electronics's most recent closing price is 231,000 won (+0.22% versus the previous session), and the signal combining foreign investors/institutional investors order flow with news and momentum reads 🟡 Neutral / Wait-and-see. With positive and negative signals mixed, this is a stock to watch closely.
Recent related news breaks down to 4 positive-catalyst items and 4 negative-catalyst items — a mixed picture.
※ Price and foreign-investor/institutional-investor order flow data are provided by Korea Investment & Securities (KIS) and reflect the time of publication.
This article is automatically summarized and analyzed based on the original news source. Read the original article (Maeil Business Newspaper - Securities)
